Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $122.61 Consensus Target Price from Brokerages

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) has received a consensus rating of "Moderate Buy" from the twenty-three brokerages that are presently covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a hold recommendation, seventeen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $122.61.

Several equities analysts have issued reports on the stock. Needham & Company LLC lowered their target price on shares of Sarepta Therapeutics from $183.00 to $125.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. HC Wainwright reissued a "neutral" rating and set a $40.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, May 22nd. Royal Bank of Canada dropped their target price on shares of Sarepta Therapeutics from $87.00 to $58.00 and set a "sector perform" rating on the stock in a report on Wednesday, May 7th. Wells Fargo & Company cut their target price on shares of Sarepta Therapeutics from $115.00 to $100.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. Finally, Scotiabank decreased their target price on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a research note on Thursday, March 20th.

Sarepta Therapeutics Stock Down 2.3%

Shares of SRPT traded down $0.89 on Friday, hitting $37.72. 3,085,574 shares of the stock traded hands, compared to its average volume of 1,734,484. Sarepta Therapeutics has a one year low of $34.10 and a one year high of $173.25. The company has a market capitalization of $3.71 billion, a PE ratio of 30.18 and a beta of 0.85. The business has a 50 day simple moving average of $50.84 and a 200 day simple moving average of $91.64. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). The business had revenue of $744.86 million during the quarter, compared to the consensus estimate of $685.75 million. Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The firm's revenue for the quarter was up 80.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.73 EPS. As a group, equities analysts forecast that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Claude Nicaise sold 2,491 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the transaction, the director now directly owns 27,812 shares in the company, valued at $2,771,187.68. The trade was a 8.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 7.70% of the company's stock.

Institutional Trading of Sarepta Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Sarepta Therapeutics by 54.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 463,342 shares of the biotechnology company's stock worth $29,570,000 after purchasing an additional 164,041 shares during the period. United Services Automobile Association bought a new stake in shares of Sarepta Therapeutics during the first quarter valued at approximately $436,000. Great Lakes Advisors LLC purchased a new position in shares of Sarepta Therapeutics in the first quarter worth $224,000. Scientech Research LLC bought a new position in shares of Sarepta Therapeutics during the first quarter worth $968,000. Finally, EcoR1 Capital LLC boosted its position in shares of Sarepta Therapeutics by 67.8% during the first quarter. EcoR1 Capital LLC now owns 1,292,386 shares of the biotechnology company's stock worth $82,480,000 after acquiring an additional 522,386 shares during the last quarter. Institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.